Scarica l'app Stockscreener
53.66
0.41%
-0.22
Dopo l'orario di chiusura:
53.76
0.10
+0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AKRO Giù?
Forum
Previsione
Precedente Chiudi:
$53.88
Aprire:
$53.95
Volume 24 ore:
5.35M
Relative Volume:
2.95
Capitalizzazione di mercato:
$4.29B
Reddito:
-
Utile/perdita netta:
$-269.44M
Rapporto P/E:
-14.31
EPS:
-3.75
Flusso di cassa netto:
$-262.63M
1 W Prestazione:
+16.55%
1M Prestazione:
+23.47%
6M Prestazione:
+50.46%
1 anno Prestazione:
+81.10%
Intervallo 1D:
$53.65
$54.08
Intervallo di 1 settimana:
$45.50
$54.53
Portata 52W:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Nome
Akero Therapeutics Inc
Settore
Industria
Telefono
650-487-6488
Indirizzo
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Confronta AKRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
53.66 | 4.32B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-04 | Iniziato | TD Cowen | Buy |
| 2025-01-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-18 | Iniziato | Citigroup | Buy |
| 2024-04-22 | Ripresa | BofA Securities | Neutral |
| 2023-09-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Iniziato | Guggenheim | Buy |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-02 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-10 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Evercore ISI | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
| 2019-07-15 | Iniziato | Jefferies | Buy |
| 2019-07-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Akero Therapeutics Inc Borsa (AKRO) Ultime notizie
Will Akero Therapeutics Inc. stock reach Wall Street targetsMarket Growth Summary & AI Optimized Trade Strategies - newser.com
Is Akero Therapeutics Inc. forming a bottoming baseJuly 2025 Closing Moves & High Yield Stock Recommendations - newser.com
Is Akero Therapeutics Inc. stock bottoming outWeekly Investment Report & Verified Stock Trade Ideas - newser.com
TD Cowen Downgrades Akero Therapeutics to Hold From Buy, Adjusts Price Target to $58 From $76 - MarketScreener
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring a 20% Upside Potential in Biotech - DirectorsTalk Interviews
Is Akero Therapeutics Inc. stock a buy before product launchesQuarterly Trade Summary & Fast Entry Momentum Trade Alerts - newser.com
Custom watchlist performance reports with Akero Therapeutics Inc.July 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
Novo Nordisk to acquire Akero Therapeutics for up to USD 5.2 billion - Medical Dialogues
Real time breakdown of Akero Therapeutics Inc. stock performanceMarket Activity Summary & Daily Momentum Trading Reports - newser.com
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion - Indian Pharma Post
The week in pharma: action, reaction and insight – week to October 10 - The Pharma Letter
Akero Therapeutics (NASDAQ:AKRO) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Akero Therapeutics' (AKRO) Peer Perform Rating Reiterated at Wolfe Research - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Cut to "Hold" at HC Wainwright - MarketBeat
Lifesci Capital Downgrades Akero Therapeutics (NASDAQ:AKRO) to Hold - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Insider Sells $576,000.00 in Stock - MarketBeat
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc.AKRO - Business Wire
Akero Therapeutics (NASDAQ:AKRO) Shares Gap UpShould You Buy? - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO) - GlobeNewswire Inc.
Akero Therapeutics Acquired by Novo Nordisk for $5.2B - The Globe and Mail
Akero Therapeutics (NASDAQ:AKRO) Cut to Hold at Jefferies Financial Group - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Downgraded by Canaccord Genuity Group to Hold - MarketBeat
Quantitative breakdown of Akero Therapeutics Inc. recent moveWeekly Profit Report & Free Low Drawdown Momentum Trade Ideas - newser.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Yahoo Finance
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
How to recover losses in Akero Therapeutics Inc. stockJuly 2025 Intraday Action & Weekly Chart Analysis and Trade Guides - newser.com
Novo Nordisk: New CEO Executing on Focused Strategy With Akero Acquisition - Morningstar Canada
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance? - Zacks Investment Research
Wolfe Research Downgrades Akero Therapeutics (AKRO) to Peer Perf - GuruFocus
Wolfe Research Downgrades Akero Therapeutics to Peer Perform From Outperform - MarketScreener
HC Wainwright Downgrades Akero Therapeutics to Neutral From Buy, $72 Price Target - MarketScreener
Novo makes bold $5.2bn bet on MASH treatment with Akero buy - BioXconomy
Akero: Novo Nordisk Acquisition Puts Focus On Unprecedented MASH Data With EFX (AKRO) - Seeking Alpha
Akero says new owner Novo Nordisk to drive commercialisation process - MarketScreener
Novo Nordisk analyst on Akero acquisition: Buys potentially best remedy for fatty liver - medwatch.com
Novo Nordisk to expand MASH portfolio with $5.2 Bn Akero Therapeutics buyout - ET Pharma
What drives Akero Therapeutics Inc 0K4 stock priceDividend Stability Analysis & Stocks With 200% Upside Potential - earlytimes.in
Is Akero Therapeutics Inc. (0K4) stock included in top ETFsBull Run & Verified Stock Trade Ideas - newser.com
Akero Therapeutics Inc. stock momentum explainedJuly 2025 Action & Momentum Based Trading Ideas - newser.com
Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger - MSN
Key facts: Novo Nordisk to Acquire Akero for $5.2 Billion; R&D Costs to Rise - TradingView
Novo Nordisk to Acquire Akero Therapeutics for $5.2B, Targeting Breakthrough Liver Drug - Azat TV
Akero Therapeutics Inc. (AKRO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Akero therapeutics CSO sells $576k in shares - Investing.com
Akero Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:AKRO - Benzinga
Novo Nordisk to acquire clinical-stage drugmaker Akero Therapeutics - MLex
Novo Nordisk’s Akero Bid Centered On Addressing Cirrhotic MASH - insights.citeline.com
Novo buys Akero for $4.7B in third and largest deal in key liver disease class - biocentury.com
Novo buying Akero for $4.7B to strengthen MASH portfolio - BioWorld MedTech
Akero Therapeutics Inc Azioni (AKRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Akero Therapeutics Inc Azioni (AKRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rolph Timothy | Chief Scientific Officer |
Oct 07 '25 |
Option Exercise |
28.35 |
12,500 |
354,375 |
179,071 |
| Rolph Timothy | Chief Scientific Officer |
Oct 07 '25 |
Sale |
46.08 |
12,500 |
576,001 |
166,571 |
| Cheng Andrew | President and CEO |
Oct 08 '25 |
Option Exercise |
0.61 |
52,212 |
32,110 |
526,114 |
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):